Replies to post #3737 on Biotech Values

[DewDiligence]

>> When you say your officially concerned, what does that mean? <<

The supply issue bears watching. If GENR cannot make enough Squalamine to conduct all of the phase-2 trials in a timely manner, that will retard the launch of the phase-3 trials and the ultimate commercialization. It could also reduce the deal value that GENR of an AMD partnership to some degree.

>> Concerned enough to sell some shares? <<

I still hold a six-figure allotment of shares because I’m confident that the clinical data in AMD will be solid and that will trump the other issues. However, I also think that GENR’s management may be overplaying its cards by holding out for a EYET-like or REGN-like blockbuster deal. Especially if there are manufacturing issues with Squalamine, GENR ought to be more realistic about the kind of deal they hope to strike. I consider the EYET and REGN deals to be aberrations.

>> Are you concerned about all the Phase II trials or just about the combo-trial?<<

The three phase-2 trials have to be considered as a unit. Without at least interim data from all of the phase-2 trials, I don’t think GENR can begin phase 3.